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uni-greifswald.deAbstractDHEA is the major precursor of human sex steroid synthesis and is inactivated via sulfonation
to DHEAS. A previous genome-wide association study related the single nucleotide
polymorphism (SNP) rs2637125, located near the coding region of DHEA sulfotransferase,
SULT2A1, to serum DHEAS concentrations. However, the functional relevance of this SNP
with regard to DHEA sulfonation is unknown. Using data from 3300 participants of the
population-based cohort Study of Health in Pomerania, we identified 43 individuals being
homozygote for the minor allele of the SNP rs2637125 (AA) and selected two sex- and age-
matched individuals with AG and GG genotype (nZ172) respectively. Steroid analysis
including measurement of serum DHEA and DHEAS was carried out by liquid
chromatography/mass spectrometry, employing steroid oxime analysis for enhancing the
sensitivity of DHEA detection. We applied quantile regression models to compare median
hormone levels across SULT2A1 genotypes. Median comparisons by SULT2A1 genotype
(AA vs AG andGG genotypes respectively) showednodifferences in the consideredhormones
including DHEAS, DHEA, androstenedione, as well as cortisol and cortisone concentrations.
SULT2A1 genotype also had no effect on the DHEA/DHEAS ratio. Sex-stratified analyses, as
well as alternative use of the SULT2A1 SNP rs182420, yielded similar negative results. Genetic
variants of SULT2A1 do not appear to have an effect on individual DHEA and DHEAS
concentrations or the DHEA/DHEAS ratio as a marker of DHEA sulfonation capacity.Key Words
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(2013) 50, 73–77IntroductionDHEAS is the most abundant steroid in human circulation
and represents the conjugated, nonactive excretion formof DHEA, which acts as the universal sex steroid
precursor and the major source of androgens in womenr the terms of the Society for
nrestricted non-commercial use,
provided the original work is properly
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decline, and at 70 years of age, circulating DHEAS
concentrations have diminished by 90% compared with
the peak levels achieved at 20–30 years of age (Orentreich
et al. 1984). This has led to widespread speculation about a
causative role of DHEAS in the development of age-related
diseases and longevity. A previous genome-wide associ-
ation study (GWAS) comprising 14 846 individuals ident-
ified eight common single nucleotide polymorphisms
(SNPs) that implicate nearby genes as independently
associated with serum DHEAS concentrations (Zhai et al.
2011), providing much needed insight into the meta-
bolism of DHEAS. Among the identified genes, SULT2A1, a
specialized sulfotransferase that converts DHEA to DHEAS
in the adrenal cortex and liver, is an obvious candidate
gene for subsequent functional studies (Rainey et al. 2002).
Previous studies have established that the relationship
between conjugated DHEAS and unconjugated DHEA is
defined by SULT2A1 activity (Hammer et al. 2005) and that
impairment of DHEA sulfonation results in low DHEAS
and concurrent androgen excess with high DHEA and
androstenedione levels (Noordam et al. 2009). But the
clinical relevance of this candidate gene identified by
GWAS with regard to individually meaningful prognostic,
diagnostic, and therapeutic information is unknown.
Therefore, we measured serum DHEAS, DHEA, and
androstenedione concentrations in a subset of
215 individuals of the Study of Health in Pomerania
(SHIP) follow-up cohort to investigate potential
differences in adrenal androgens, including the DHEA/
DHEAS ratio, related to SULT2A1 genotypes.Materials and methods
Study population
The SHIP is a population-based cohort study conducted in
the northeastern area of Germany. Details on the SHIP
study design, recruitment, and procedures have been
published previously (Vo¨lzke et al. 2011). The net sample
drawn for the SHIP comprised 6265 eligible individuals
(3160 women) with German citizenship and main
residency in the study area, whereof 4308 (2192 women)
aged 20–80 years finally participated in the baseline study
(SHIP-0) between 1997 and 2001 (response 68.8%). During
the 5-year follow-up (SHIP-1) between 2002 and 2006,
3300 (1711 women) participants were reexamined
(response proportion 83.6%). All participants gave
informed written consent. A review board of independent
scientists monitored the study. The study protocol ishttp://www.jme.endocrinology-journals.org
DOI: 10.1530/JME-12-0185
 2013 Society for Endocrinology
Printed in Great Britainconsistent with the principles of the Declaration of
Helsinki, as reflected by an a priori approval of the Ethics
Committee of the University of Greifswald. To assess the
differences in adrenal androgens related to SULT2A1
genotype, we identified 43 individuals homozygote for
the minor allele of SNP rs2637125 (AA), additionally
selected two sex- and age-matched individuals having AG
and GG genotype (nZ86 each) respectively, and finally
measured adrenal androgens in the serum of these
215 participants of the follow-up study SHIP-1.
Anthropometric measurements were taken and BMI
was calculated from the body weight in kilogram and
height in meters according to the formula: kg/m2. A
summative cardiovascular disease (CVD) score was built
upon diagnosis of angina pectoris, peripheral artery
disease, heart failure, stroke, or myocardial infarction.
HbA1c concentrations were determined by HPLC (Bio-Rad
Diamat). Diabetes mellitus was defined based on self-
reported physicians’ diagnosis or use of antidiabetic
medication (ATC code A10) in the last 7 days, or HbA1c
concentrationsR6.5%. All blood samples had been drawn
from the cubital vein between 0800 and 1800 h with
participants in the supine position, and serum aliquots
had been stored at K80 8C until analysis.Steroid analysis
Steroids were measured by liquid chromatography/
tandem mass spectrometry (LC–MS/MS) employing a
Waters Xevo mass spectrometer with Acquity uPLC
system, fitted with a HSS T3, 1.8 mm, 1.2!50 mm column.
LC–MS/MS conditions were an electrospray ionization
source with capillary voltage 4.0 kV, a source temperature
of 150 8C, and a desolvation temperature of 500 8C. Steroid
oxime analysis, which facilitates enhanced detection,
i.e. increased sensitivity, by formation of oxime deriva-
tives of the steroid oxo-groups (Kushnir et al. 2006), was
employed for the measurement of DHEA and androstene-
dione and carried out in positive mode, whereas DHEAS
measurement was performed in negative mode. DHEA,
androstenedione, cortisol, and cortisone were extracted
from 150 ml serum via liquid–liquid extraction using 1 ml
tert-butyl-methyl-ether followed by derivatization into
steroid oximes employing 100 ml derivatization mixture
(0.16 g hydroxylamine in 8 ml pyridine). For protein
precipitation and extraction of DHEAS, 20 ml ZnSO4
0.1 mM and 100 ml acetonitrile were added to 20 ml
serum before evaporation under constant flow of nitrogen.
All steroids were separated using an optimized gradient
system consisting of methanol with 0.1% formic acid andPublished by Bioscientifica Ltd.
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appropriate internal standards, ranging from 0.1 to
250 ng/ml for steroid oxime analysis and 250 to
100 000 ng/ml for DHEAS analysis. Each steroid was ident-
ified by matching retention times and two mass transitions
in comparison to a deuterated reference compound.Statistical analyses
Continuous data are expressed as median (25th and
75th percentiles) and quantitative data as percentage.
Given the broad age range of our study population, we
performed linear regression analyses modeling continuous
age and DHEA/DHEAS ratio variables, but without any
indication of a potential age dependency. Individuals
being homozygote for the rs2637125 minor allele (AA)
were used as reference group (AG vs AA and GG vs AA).
Alternatively, we also modeled the SULT2A1 SNP rs182420
with homozygous minor alleles (TT) as reference group
(Goodarzi et al. 2007). Quantile regression models were
used to compare median levels and calculate pairwise
P values for continuous variables. Differences in categori-
cal variables across allele pattern were assessed by pairwise
c2 tests. To detect potential sex-specific differences, we
repeated our analyses separately for men and women.
All statistical analyses were performed using STATA 11.0
(Stata Corporation, College Station, TX, USA).Results
Comparing median hormone levels by SULT2A1 genotype
(AA vs AG and GG genotypes respectively), the conductedTable 1 Characteristics of the study population by SULT2A1 genoty
75th percentiles) or percentage. The maximum number of observa
nZ204, DHEA/DHEAS ratio: nZ204, cortisol and cortisone: nZ213.
and calculate pairwise P values for continuous variables and pairwi
Variable AA (nZ43) AG (nZ8
Age (years) 49.0 (40.0, 72.0) 50.0 (43
DHEA (nmol/l) 16.6 (11.4, 22.6) 17.3 (11
DHEAS (nmol/l) 4767 (2467, 7841) 5607 (23
DHEA/DHEAS ratio (nmol/l) 0.004 (0.002, 0.005) 0.003 (0
Cortisol (nmol/l) 81.9 (51.1, 122.9) 89.8 (64
Cortisone (nmol/l) 31.8 (23.6, 44.7) 38.9 (30
Androstenedione (nmol/l) 1.6 (1.1, 2.5) 2.4 (1.1,
Blood sampling time (24 h) 11:00 (9, 12) 12:00 (1
Current smoker (%) 37.2 30.2
BMI (kg/m2) 26.9 (24.5, 29.8) 26.7 (24
Cardiovascular disease (%) 18.6 16.5
Diabetes mellitus (%) 11.6 9.3
http://www.jme.endocrinology-journals.org
DOI: 10.1530/JME-12-0185
 2013 Society for Endocrinology
Printed in Great Britainquantile regression models did not show any significant
differences in the considered hormones including DHEA,
DHEAS, cortisol, cortisone, or androstenedione concen-
trations (Table 1). SULT2A1 genotype also had no impact
on the DHEA/DHEAS ratio. There were also no differences
with regard to age, BMI, smoking, CVD, or diabetes
mellitus. We found a borderline significant (P valueZ0.037)
difference between AA and GG genotypes with regard to
cortisol concentrations (Table 1). A scatterplot of the
actual DHEA and DHEAS concentration by SULT2A1
genotype also failed to reveal clearly separated groups
(Fig. 1). Analyses of the alternative SULT2A1 SNP rs182420
showed comparable negative results as for the main
analysis, with similar borderline significant differences in
cortisol concentrations (P valueZ0.044) between TT and
CC genotypes. Finally, sex-specific analyses of both
SULT2A1 SNPs revealed a significantly higher DHEA/
DHEAS ratio among men with SULT2A1 SNP rs2637125
AA genotype compared with men with AG (P valueZ0.006)
and GG (P valueZ0.019) genotype. As we identified no
differences in blood sampling time between the groups,
co-incidental group-specific variations in sampling time
could be ruled out to explain this finding as a consequence
of the diurnal rhythm of cortisol secretion.Discussion
The present post-GWAS functional study revealed no
significant differences in DHEA or DHEAS concentrations
with regard to SULT2A1 genotype, a potential candidate
gene predictive of low serum DHEAS concentrationspe (rs2637125). Values shown are expressed as median (25th and
tions was used for each measurement: DHEA: nZ214, DHEAS:
We used quantile regression models to compare median levels
se c2 tests for categorical variables
6)
AG vs AA
P value GG (nZ86)
GG vs AA
P value
.0, 72.0) 0.867 49.5 (42.0, 72.0) 0.989
.9, 25.2) 0.759 17.3 (12.9, 23.3) 0.772
37, 10 116) 0.417 5735 (3601, 10 689) 0.320
.002, 0.006) 0.506 0.003 (0.002, 0.005) 0.446
.4, 142.5) 0.593 108.7 (65.7, 143.9) 0.037
.0, 53.1) 0.189 41.1 (29.2, 52.5) 0.071
3.6) 0.162 2.0 (1.3, 3.4) 0.521
0, 13) 0.450 11:00 (10, 13) 0.999
0.173 30.2 0.379
.7, 29.3) 0.815 27.9 (25.1, 32.2) 0.269
0.762 17.4 0.871
0.679 9.3 0.679
Published by Bioscientifica Ltd.
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Figure 1
Concentrations of DHEA to DHEAS by SULT2A1 genotype. Individuals with
AA genotype (nZ39) were compared with sex- and age-matched
individuals carrying the AG genotype (nZ83) and GG genotype (nZ82) of
the SNP rs2637125, all drawn from the SHIP follow-up study (nZ3300).
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individuals (Zhai et al. 2011).
SULT2A1, also termed DHEA sulfotransferase, is a
specialized sulfotransferase that catalyzes the sulfonation
of steroids and detoxification of bile acids in the liver and
adrenal glands (Strott 2002). In this study, we were not able
to detect any differences in median DHEA and DHEAS
concentrations across the different SULT2A1 genotype
groups. Furthermore, SULT2A1 genotype showed no impact
on the conversion of DHEA into DHEAS, as indicated by the
lack of a significant difference between the group-specific
DHEA/DHEAS ratio, previously established as a valid
surrogate marker for DHEA sulfonation capacity (Arlt et al.
2006, Noordam et al. 2009). These findings are in line with
previous studies lacking any impact of SULT2A1 allelic
variants on serum adrenal hormones among African-
American men (Wilborn et al. 2006), Finnish prepubertal
children (Utriainen et al. 2012), or white women with
polycystic ovary syndrome (PCOS; Goodarzi et al. 2007).
The latter study found only one particular SNP (rs182420)
within the SULT2A1 gene related to lower DHEAS concen-
trations in women with PCOS, but not in women without
PCOS (Goodarzi et al. 2007). Similarly, we were not able to
detect an association of SULT2A1 SNP rs182420 with DHEA
or DHEAS concentrations among men or women from the
general population.
Although the applied SNP rs2637125 was not the most
strongly (PZ2.61!10K19) associated with DHEAS concen-
trations in the previous GWAS (the strongest hit was
rs11761528 on ZKSCAN5 with PZ3.15!10K36), it was
located only 12 kb downstream of the functionally very
relevant protein-coding gene SULT2A1 (Zhai et al. 2011).
However, potential explanations for the absent differenceshttp://www.jme.endocrinology-journals.org
DOI: 10.1530/JME-12-0185
 2013 Society for Endocrinology
Printed in Great Britainin the actual DHEA and DHEAS concentrations with
regard to SULT2A1 genotype might relate to the unknown
impact of this SNP on SULT2A1 transcription and
expression. Previous studies examining regulatory
mechanisms of SULT2A1 mRNA expression and enzymatic
activity identified several factors as potent inhibitors of
SULT2A1 expression (McAllister & Hornsby 1988, Fang
et al. 2007). For example, cytokines such as transforming
growth factor-b (TGF-b) and tumor necrosis factor-a
(TNF-a) have been found to decrease adrenal cell
SULT2A1 mRNA levels (Parker et al. 1998). Decreased
SULT2A1 activity was also observed during the acute-
phase response in a time- and dose-dependent manner in a
murine model (Kim et al. 2004) and in patients with acute
sepsis (Arlt et al. 2006). Also the transcriptional regulation
via transcription factors SF-1 and GATA-6 might be an
important modulator of SULT2A1 expression and the
production of adrenal DHEAS (Saner et al. 2005). In light of
these limitations, the present data (although demonstrat-
ing no impact of SULT2A1 genotype on actual DHEA and
DHEAS concentrations) could not ultimately rule out a
potential influence of SULT2A1 on mechanisms regulating
DHEAS production in the human adrenal.
Asking what GWAS will mean to the clinical endo-
crinologist, the present post-GWAS functional study puts
further weight on the notion that candidate genes
identified by GWAS do not necessarily translate into
clinically meaningful prognostic, diagnostic, and thera-
peutic information for individuals (McCarthy 2009).
However, given the generally small proportion of inter-
individual variability in disease predisposition explained
by single genetic variants (Maher 2008), GWAS could only
be a first step and essential starting point for the molecular
classification of disease subtypes and the subsequent
translation into novel therapeutic and preventative
approaches (Haring & Wallaschofski 2012).Declaration of interest
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